Use of Darunavir-Cobicistat as a Treatment Option for Critically Ill Patients with SARS-CoV-2 Infection
Yonsei Medical Journal 2020³â 61±Ç 9È£ p.826 ~ p.830
±èÀºÁø(Kim Eun-Jin) - Daegu Catholic University Medical Center Division of Pulmonary and Critical Care Medicine
ÃÖ¼±ÇÏ(Choi Sun-Ha) - Kyungpook National University Chilgok Hospital Division of Pulmonary and Critical Care Medicine
¹ÚÀç¼®(Park Jae-Seok) - Keimyung University School of Medicine Keimyung University Dongsan Hospital Department of Internal Medicine
±Ç¿ë½Ä(Kwon Yong-Shik) - Keimyung University School of Medicine Keimyung University Dongsan Hospital Department of Internal Medicine
ÀÌÀçÈñ(Lee Jae-Hee) - Kyungpook National University School of Medicine Department of Internal Medicine
±è¿¬Àç(Kim Yeon-Jae) - Daegu Fatima Hospital Division of Pulmonary and Critical Care Medicine
À̽ſ±(Lee Shin-Yup) - Kyungpook National University Chilgok Hospital Division of Pulmonary and Critical Care Medicine
ÃÖÀº¿µ(Choi Eun-Young) - Yeungnam University Medical Center Division of Pulmonary and Critical Care Medicine
Abstract
We retrospectively reviewed patients with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections who were admitted to an intensive care unit in Daegu, South Korea. The outcomes of patients who did (cases) or did not (controls) receive darunavir-cobicistat (800?150 mg) therapy were compared. Fourteen patients received darunavir-cobicistat treatment, and 96 received other antiviral therapy (controls). Overall, the darunavir-cobicistat group comprised patients with milder illness, and the crude mortality rate of all patients in the darunavir-cobicistat group was lower than that in the controls [odds ratio (OR) 0.20, 95% confidence interval (CI) 0.04?0.89, p=0.035]. After 1:2 propensity-score matching, there were 14 patients in the darunavir-cobicistat group, and 28 patients in the controls. In propensity score-matched analysis, the darunavir-cobicistat group had lower mortality than the controls (OR 0.07, 95% CI 0.01?0.52, p=0.009). In conclusion, darunavir-cobicistat therapy was found to be associated with a significant survival benefit in critically ill patients with SARS-CoV-2 infection.
Å°¿öµå
Coronavirus disease 2019, severe acute respiratory syndrome coronavirus 2, darunavir-cobicistat
¿ø¹® ¹× ¸µÅ©¾Æ¿ô Á¤º¸
µîÀçÀú³Î Á¤º¸
À¯È¿¼º°á°ú(Recomendation)
In propensity score-matched analysis, the darunavir-cobicistat group had lower mortality than the controls (OR 0.07, 95% CI 0.01–0.52, p=0.009); darunavir-cobicistat therapy was found to be associated with a significant survival benefit in critically ill patients with SARS-CoV-2 infection.